Hospital News
More on Eye Cancer
- Bexxar Effective as First-Line Treatment for Non-Hodgkin's Lymphoma Patients When Used With Chemotherapy
- Cancer Treatment Is First to Directly Target Tumor Blood Supply in Patients
- Combination of Abbreviated Chemotherapy with Radioactive Monoclonal Antibody Effective in Previously Untreated Non-Hodgkin's Lymphoma
- Coping With Chronic Cancer Pain
- Do Heart Disease and Cancer Have a Common Genetic Link?
- Health Effects of Secondhand Smoke Studied in First-of-Its-Kind Series of Clinical Studies
- Integrative Therapies Program for Children with Cancer at Morgan Stanley Children's Hospital of NewYork-Presbyterian Receives Gift Commitment from Origins Natural Resources
- Message to the Elderly: It's Never Too Late to Prevent Illness!
- New Book by Weill Cornell Psychiatrist Offers Insight and Hope for "Surviving Cancer Emotionally"
- NewYork-Presbyterian/Weill Cornell Creates World-Class Cancer Center
- NewYork-Presbyterian Hospital's Weill Cornell Medical Center Announces Preliminary Lung Cancer Data Involving Patients Treated With Arthritis Medication
- The Seventh Issue of Cancer Prevention Has Arrived!
- Tumor Size Predicts Survival in Most Common Type of Lung Cancer
- Two Novel Biologics Studied for Multiple Myeloma
- Weill Cornell Researchers Announce New Gene Therapy Strategy To Promote Hair Growth
Health Library
Clinical Services
More on Eye Cancer
- Bladder Cancer
- Blood Cancer
- Brain Cancer
- Center for Holistic Urology
- Center for Lymphoma and Myeloma
- Colon Cancer
- Early Lung Cancer Action Program
- Edward S. Harkness Eye Institute
- Gastrointestinal Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Head and Neck Surgery
- Kidney Cancer
- Leukemia and Myeloproliferative Disease Center
- Lung Cancer
- Mesothelioma
- Oncology (Cancer)
- Pediatric Cancer
- Prostate Cancer
- Rectal Cancer
- Robert M. Ellsworth Ophthalmic Oncology Center
- Soft Tissue and Bone Cancer
- Spirit of Care Program
- Stomach Cancer
- Testicular Cancer
- Urologic Cancer
Eye Cancer
NewYork-Presbyterian Cancer Centers bring together two major programs for diagnosis, treatment, and research on adult and pediatric cancers of the eye and tissues (including muscles and nerves) of the orbit – the bony socket that surrounds the eye.
The Department of Ophthalmology at NewYork-Presbyterian Hospital/Columbia University Medical Center is a regional referral center for orbital tumors, screening approximately 100 new cases annually. Its multidisciplinary Skull Base Surgery team, which meets monthly to discuss cases and the latest research, combines the expertise of distinguished ophthalmologists, neurosurgeons, otolaryngology's, plastic surgeons, radiation oncologists, and interventional neuroradiologists to diagnose and treat cancers involving the orbit, brain, and paraorbital sinuses. NewYork-Presbyterian/Columbia remains at the forefront of developments in these types of cancers. Its Harkness Eye Institute is a member of the International Orbit Society, a study group that shares information regarding orbital diseases and sponsors multicenter clinical studies.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center is home to one of the world's largest referral centers for ocular tumors, caring for adults and children with various ocular and orbital tumors. Its Ocular Oncology Center has the latest ultrasound equipment for evaluating and measuring melanomas for both diagnosis and treatment planning. The Robert M. Ellsworth Ophthalmic Oncology Center at NewYork- Presbyterian/Weill Cornell is leading the multicenter Collaborative Ocular Melanoma Study (COMS), now in its 14th year.Pediatric Eye Cancers
Morgan Stanley Children's Hospital and NewYork-Presbyterian/Weill Cornell are members of the national Children's Oncology Group (COG) – a multi-institutional clinical research collaboration that sponsors protocols to treat children diagnosed with common solid orbital malignancies. The Robert M. Ellsworth Ophthalmic Oncology Center at NewYork-Presbyterian/Weill Cornell is the longest-running center in the world for the diagnosis and treatment of childhood eye cancer, with particular expertise in retinoblastoma, a rare pediatric cancer. Its team has collaborated with colleagues at the Memorial Sloan-Kettering Cancer Center on a protocol for the management of extraocular disease, which has achieved cure rates as high as 50% among children with metastatic retinoblastoma. The team is continuing to study the use of systemic and periocular chemotherapy for retinoblastoma and has found that periocular carboplatin can reach eye tumors and can be used in addition to systemic chemotherapy for intraocular disease.
Hospital News
- Bexxar Effective as First-Line Treatment for Non-Hodgkin's Lymphoma Patients When Used With Chemotherapy
- Cancer Treatment Is First to Directly Target Tumor Blood Supply in Patients
- Combination of Abbreviated Chemotherapy with Radioactive Monoclonal Antibody Effective in Previously Untreated Non-Hodgkin's Lymphoma More
